These old drugs in a new regime will be a useful salvage." Sir Paul Nurse, director general of Imperial Cancer Research Fund, said: "We've been waiting for good news on ovarian cancer for some ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

Get Instant Summarized Text (Gist) AI was used to analyze how ovarian cancer cells respond to drugs when cultured with fibroblasts, which are crucial in the tumor microenvironment. The study ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

(Reuters) -Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The company's ...

Elahere is the first drug to improve survival in platinum-resistant ovarian cancer. "Ovarian cancer can be devastating and, when cancer cells stop responding to chemotherapy, patients may feel ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Company's shares hit all-time high after trial success Corcept plans to file US marketing application in third quarter Drug relacorilant may get broader label than competitors, analyst says March ...